A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Status:
RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.